NASDAQ : LTGO
Latigo Biotherapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 15.54 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.03B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Selling, General & Admin | 15.60M | 10.86M | 6.67M |
| Research & Development | 96.78M | 99.53M | 56.78M |
| Operating Expenses | 112.38M | 110.39M | 63.45M |
| Operating Income | -112.38M | -110.39M | -63.45M |
| Interest & Investment Income | 2.30M | 2.94M | 2.26M |
| Other Non Operating Income (Expenses) | -804.00K | -1.72M | 4.00K |
| Pretax Income | -111.14M | -109.17M | -61.18M |
| Net Income | -111.14M | -109.17M | -61.18M |
| Net Income to Common | -111.14M | -109.17M | -61.18M |
| Shares Outstanding (Basic) | 952.01K | 844.73K | 679.09K |
| Shares Outstanding (Diluted) | 952.01K | 844.73K | 679.09K |
| EPS (Basic) | -116.74 | -129.23 | -90.10 |
| EPS (Diluted) | -116.74 | -129.23 | -90.10 |
| Free Cash Flow | -103.30M | -97.69M | -51.03M |
| Free Cash Flow Per Share | -108.51 | -115.65 | -75.14 |
| EBITDA | -112.16M | -110.14M | -63.21M |
| D&A For EBITDA | 215.00K | 249.00K | 244.00K |
| EBIT | -112.38M | -110.39M | -63.45M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Cash & Equivalents | 55.00M | 69.44M | 17.92M |
| Cash & Short-Term Investments | 55.00M | 69.44M | 17.92M |
| Prepaid Expenses | 3.32M | 2.18M | 3.25M |
| Restricted Cash | 194.00K | 192.00K | |
| Other Current Assets | 682.00K | 2.02M | |
| Total Current Assets | 59.20M | 73.83M | 21.16M |
| Property, Plant & Equipment | 1.76M | 1.07M | 1.41M |
| Other Long-Term Assets | 501.00K | 616.00K | 290.00K |
| Total Assets | 64.76M | 75.52M | 22.86M |
| Accounts Payable | 3.57M | 5.01M | 7.07M |
| Accrued Expenses | 12.26M | 12.87M | 6.73M |
| Current Portion of Leases | 705.00K | 563.00K | 387.00K |
| Other Current Liabilities | 5.15M | 250.00K | |
| Total Current Liabilities | 51.58M | 18.45M | 14.44M |
| Long-Term Leases | 648.00K | 127.00K | 464.00K |
| Other Long-Term Liabilities | 35.00K | 35.00K | 35.00K |
| Total Liabilities | 52.26M | 18.61M | 14.93M |
| Additional Paid-In Capital | 15.81M | 11.46M | 4.37M |
| Retained Earnings | -291.89M | -243.13M | -133.96M |
| Total Common Equity | -276.08M | -231.67M | -129.60M |
| Shareholders' Equity | 12.50M | 56.91M | 7.93M |
| Total Liabilities & Equity | 64.76M | 75.52M | 22.86M |
| Total Debt | 31.25M | 690.00K | 851.00K |
| Net Cash (Debt) | 23.75M | 68.75M | 17.07M |
| Net Cash Per Share | 24.95 | 81.38 | 25.13 |
| Filing Date Shares Outstanding | 66.30M | 878.52K | 679.09K |
| Total Common Shares Outstanding | 988.24K | 878.52K | 679.09K |
| Working Capital | 7.62M | 55.38M | 6.73M |
| Book Value Per Share | -279.37 | -263.71 | -190.84 |
| Tangible Book Value | -276.08M | -231.67M | -129.60M |
| Tangible Book Value Per Share | -279.37 | -263.71 | -190.84 |
| Machinery | 1.40M | 1.30M | 1.26M |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Net Income | -111.14M | -109.17M | -61.18M |
| Depreciation & Amortization | 215.00K | 249.00K | 244.00K |
| Stock-Based Compensation | 7.69M | 6.72M | 2.77M |
| Other Operating Activities | 1.34M | 2.12M | 327.00K |
| Change in Accounts Payable | -1.96M | -1.96M | 5.75M |
| Change in Other Net Operating Assets | 387.00K | 4.48M | 1.14M |
| Operating Cash Flow | -103.19M | -97.56M | -50.95M |
| Capital Expenditures | -111.00K | -136.00K | -72.00K |
| Investing Cash Flow | -111.00K | -136.00K | -72.00K |
| Issuance of Common Stock | 348.00K | 117.00K | 607.00K |
| Financing Cash Flow | 84.01M | 149.50M | 607.00K |
| Net Cash Flow | -19.29M | 51.80M | -50.42M |
| Free Cash Flow | -103.30M | -97.69M | -51.03M |
| Free Cash Flow Per Share | -108.51 | -115.65 | -75.14 |
| Levered Free Cash Flow | -59.47M | ||
| Unlevered Free Cash Flow | -59.47M | ||
| Change in Working Capital | -1.57M | 2.52M | 6.89M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Market Capitalization | 908.30M | ||
| Enterprise Value | 884.55M | ||
| Debt / Equity Ratio | 2.50 | 0.01 | 0.11 |
| Net Debt / Equity Ratio | -1.90 | -1.21 | -2.15 |
| Net Debt / EBITDA Ratio | 0.21 | 0.62 | 0.27 |
| Net Debt / FCF Ratio | 0.23 | 0.70 | 0.33 |
| Quick Ratio | 1.07 | 3.76 | 1.24 |
| Current Ratio | 1.15 | 4.00 | 1.47 |
| Return on Equity (ROE) | -336.74% | ||
| Return on Assets (ROA) | -140.26% | ||
| Return on Capital Employed (ROCE) | -852.30% | -193.40% | -752.80% |
| Buyback Yield / Dilution | -24.39% |